M. Brennan

Biography

 Pacific Edge Limited (NZX: PEB) is a New Zealand publicly-listed, cancer diagnostics company specialising in the discovery and commercialisation of diagnostic and prognostic tests for better detection and monitoring of cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally through its wholly owned central laboratories in New Zealand and the USA. The company’s products have been tested and validated in international multi-centre clinical studies. Pacific Edge has two proprietary, novel, accurate, molecular diagnostic products in-market providing more accurate, and better detection and management of urothelial cancer. Cxbladder Detect is available through the company’s dedicated CLIA certified laboratories for customers in New Zealand, Australia and the USA. Cxbladder Triage is available in New Zealand and Australia and will launch in the USA in 2015. Cxbladder Detect Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of a patients’ urine. Cxbladder Detect was launched in 2013 in the USA and is commercially available in New Zealand, Australia and the USA as a Laboratory Developed Test (LDT) from the company’s CLIA certified laboratories. Cxbladder Detect provides physicians and clinicians with a quick, cost effective and accurate measure of the presence of the cancer as an effective adjunct to cystoscopy. Cxbladder Triage Cxbladder Triage combines the power of the genomic biomarkers with extra phenotypic and clinical risk factors to accurately identify and remove patients with haematuria who have a low probability of bladder cancer, from requiring a full-urological work-up. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation and is intended to reduce of the number of patients needing an expensive and invasive work-up for urothelial cancer.

Research Interest

 Pacific Edge Limited (NZX: PEB) is a New Zealand publicly-listed, cancer diagnostics company specialising in the discovery and commercialisation of diagnostic and prognostic tests for better detection and monitoring of cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally through its wholly owned central laboratories in New Zealand and the USA. The company’s products have been tested and validated in international multi-centre clinical studies. Pacific Edge has two proprietary, novel, accurate, molecular diagnostic products in-market providing more accurate, and better detection and management of urothelial cancer. Cxbladder Detect is available through the company’s dedicated CLIA certified laboratories for customers in New Zealand, Australia and the USA. Cxbladder Triage is available in New Zealand and Australia and will launch in the USA in 2015. Cxbladder Detect Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of a patients’ urine. Cxbladder Detect was launched in 2013 in the USA and is commercially available in New Zealand, Australia and the USA as a Laboratory Developed Test (LDT) from the company’s CLIA certified laboratories. Cxbladder Detect provides physicians and clinicians with a quick, cost effective and accurate measure of the presence of the cancer as an effective adjunct to cystoscopy. Cxbladder Triage Cxbladder Triage combines the power of the genomic biomarkers with extra phenotypic and clinical risk factors to accurately identify and remove patients with haematuria who have a low probability of bladder cancer, from requiring a full-urological work-up. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation and is intended to reduce of the number of patients needing an expensive and invasive work-up for urothelial cancer.